Our Charlotte’s Web™ CBD Gummies: Calm are formulated to help you meet life’s stressful situations with ease and better focus. Stop everyday stresses while supporting a sense of calm and relaxation with a botanical blend of lemon balm, L-theanine and whole-plant hemp extract.~ 60 Count
Cannabidiol is a chemical in the Cannabis sativa plant, also known as marijuana or hemp. Over 80 chemicals, known as cannabinoids, have been identified in the Cannabis sativa plant. While delta-9-tetrahydrocannabinol (THC) is the major active ingredient in marijuana, cannabidiol is also obtained from hemp, which contains only very small amounts of THC.
Cannabidiol has effects on the brain. The exact cause for these effects is not clear. However, cannabidiol seems to prevent the breakdown of a chemical in the brain that affects pain, mood, and mental function. Preventing the breakdown of this chemical and increasing its levels in the blood seems to reduce psychotic symptoms associated with conditions such as schizophrenia. Cannabidiol might also block some of the psychoactive effects of delta-9-tetrahydrocannabinol (THC). Also, cannabidiol seems to reduce pain and anxiety.
Our Charlotte’s Web™ CBD hemp extract gummies are formulated with our full-spectrum hemp extract and contain 10 mg of CBD hemp extract and 3 mg of melatonin in every serving to help you float off to dreamland.
Charlotte’s Web™ CBD oil products include whole-plant hemp extracts from Charlotte’s Web™ plants. The extracts contain a unique blend of cannabinoids plus terpenes and flavonoids. Cannabinoids are phytocompounds that are produced by the hemp plant.
In case you didn’t get the memo, what’s popularly known as “Cannabis 2.0” is coming to Canada on Oct. 17 as the nation finally legalizes cannabis-infused beverages, edibles, vapes, and similar products. Owners of Aurora Cannabis (NYSE:ACB) stock could potentially be sitting on a green-hued gold mine if the pot-stock sector explodes to the upside in the wake of this historic event.
Aurora has been granted a processing license from Health Canada (the nation’s regulatory agency) for a facility known as Aurora Air. This particular facility will produce edible products including chocolates and gummies, which are expected to go public in Canada as soon as December of this year.
I consider that to be a very forward-thinking move on Aurora’s part, as edibles don’t carry the stigma that vaping products do. The fact that Health Canada granted the Aurora Air license, moreover, is a sign that the nation’s regulators accept and embrace edibles as a publicly purveyed commodity; you can love ’em or hate ’em, but edibles are here to stay.
The management team at Canopy Growth revealed some really positive developments, but also some very painful ones incurred by the business.
In its latest quarter, the company posted a record harvest that indicates strong sales moving forward. However, pricing, declining cash balances, and continued negative cash flows are all concerns that investors need to keep in mind.
Pain just keeps building up for the players in the cannabis space. In its latest filing, for instance, the management team at Canopy Growth Corp. (CGC) revealed that, despite posting strong sales and volume growth in the first quarter of its 2020 fiscal year, it’s still unable to generate a profit.
Add to this continued declines in its cash on hand, poor recreational cannabis pricing, and the prospect of some industry oversupply issues, and investors are right to be concerned. Even though, in the long run, Canopy will likely dominate the space as one of the few major players in the market, in the short run it looks like shareholders could be in for a world of hurt if current trends continue.
Management did say that during the quarter they happened to harvest 40,960kg of the plant, up 323% from the 9,685kg harvested one year earlier. The amount actually harvested during the quarter was well above the 34,000kg worth previously forecasted, and over 70% of what was produced fits the company’s definition of “high THC” strains. This should translate into far higher sales in the next quarter or two, meaning that this prior quarter may have been more of a bump in the road on Canopy’s road to growth.
Canopy Growth Q1 2020 Earnings Preview
Canopy Growth (OTC:CGC) is scheduled to announce Q1 earnings results on Wednesday, August 14th, after market close.
The consensus EPS Estimate is -$0.31 (+22.5% Y/Y) and the consensus Revenue Estimate is $84.62M (+226.7% Y/Y).
Over the last 1 year, cgc has beaten EPS estimates 0% of the time and has beaten revenue estimates 75% of the time.
Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 5 downward.
Zynerba’s Zygel Can Beat Epidiolex
Zynerba jumped on news of a patent for cannabidiol-based treatment of autism spectrum disorder.
The product, Zygel, allows for absorption of CBD without contact with the digestive system, preserving CBD from decomposition into THC.
GW Pharmaceuticals’ Epidiolex does pass through the digestive system, which may be responsible for somnolence and liver abnormalities reported.
Still, the stock is highly dependent on sentiment across the wider cannabis space, which could turn south unpredictably.
Dilutive financings are in Zynerba’s future, and it will be years before it sees any significant revenues from Zygel.
There is perhaps no more hated industry in market history than tobacco. But since 1926, no industry has delivered better total returns, and on a risk-adjusted basis, tobacco is #2.
Over the past 33 years, Altria and British American have delivered 18% and 14% CAGR total returns, respectively, “smoking” the S&P 500 while offering generous, recession-resistant and exponentially growing dividends.
Both companies have wide moat businesses, with proven track records of adapting to an endless stream of “existential” crises, which is why I recently bought both for my retirement portfolio.
From today’s valuations, 20% historically undervalued for MO and 25% for BTI, these defensive, high-yield blue chips can realistically deliver 12% to 20% CAGR and 19% to 25% CAGR total returns over the next five years, respectively.
Heineken And Cannabis Go Well Together
Lagunitas, a subsidiary of Heineken, brought a new cannabis-infused beverage on the market.The product is selling well, and demand is increasing rapidly.The successful launch will not bring in a lot of money (yet).
On June 26, 2018, Lagunitas, a subsidiary of Heineken (OTCQX:HEINY), announced that it will launch an IPA-inspired sparkling water which contains hops and is infused with THC and/or CBD. Both of the ingredients
HEXO (HEXO) closed at $4.91 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500’s daily loss of 0.62%. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 0.74%.
Prior to today’s trading, shares of the cannabis producer had lost 14.24% over the past month. This has lagged the Medical sector’s loss of 1.47% and the S&P 500’s gain of 2.8% in that time.